Abstract
The association of central corneal thickness (CCT) with primary open-angle glaucoma (POAG) remains uncertain. Although, several observational studies assessing this relationship, have reported an inverse association between CCT and POAG, this could be the result of collider bias. In this study, we leveraged human genetic data to assess through Mendelian randomization (MR) the effect of CCT on POAG risk, and whether this effect is mediated by intraocular pressure (IOP) changes. We used 24 single-nucleotide polymorphisms (SNPs) associated with CCT (P-value < 5×10-8) from a genome-wide association study (GWAS) (N = 17,803) provided by the International Glaucoma Genetics Consortium and 53 SNPs associated with IOP (P-value < 5×10-8) from a GWAS of UK Biobank (UKBB) (N = 97,653). We related these instruments with POAG using a GWAS meta-analysis of 8,283 POAG cases and 753,827 controls from UKBB and FinnGen. MR analysis suggested a positive association between CCT and POAG (odds ratio of POAG per 50μm increase in CCT: 1.38; 95% confidence interval: 1.18 to 1.61; p-value < 0.01). MR mediation analysis showed that 28.4% of the total effect of CCT on POAG risk was mediated through changes in IOP. The primary results were consistent with estimates of pleiotropy-robust MR methods. In conclusion, contrary to most observational studies, our results support a positive effect of CCT on the risk of POAG.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
